{"title":"[Research progress on the pathogenesis and clinical treatment of cirrhotic cardiomyopathy].","authors":"K Y Wang, L Liu","doi":"10.3760/cma.j.cn501113-20251013-00431","DOIUrl":null,"url":null,"abstract":"<p><p>Liver cirrhosis is often accompanied by cardiovascular lesions, including hyperdynamic circulatory states and myocardial lesions. The hyperdynamic circulatory state manifests as increased cardiac output, peripheral vasodilation, and decreased mean blood pressure. Cirrhotic cardiomyopathy involves impaired cardiac systolic and/or diastolic function, ventricular cavity enlargement or ventricular hypertrophy, and electrophysiological abnormalities. The pathogenesis of cirrhotic cardiomyopathy remains unclear, but gases such as nitric oxide, inflammatory factors, oxidative stress systems, apoptotic factors, sympathetic and parasympathetic nervous systems, endocannabinoid systems, and ion channels all play a role. The treatment of cirrhotic cardiomyopathy is primarily limited to animal studies; however, albumin has clinical therapeutic effectiveness.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 5","pages":"494-501"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13223771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20251013-00431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Liver cirrhosis is often accompanied by cardiovascular lesions, including hyperdynamic circulatory states and myocardial lesions. The hyperdynamic circulatory state manifests as increased cardiac output, peripheral vasodilation, and decreased mean blood pressure. Cirrhotic cardiomyopathy involves impaired cardiac systolic and/or diastolic function, ventricular cavity enlargement or ventricular hypertrophy, and electrophysiological abnormalities. The pathogenesis of cirrhotic cardiomyopathy remains unclear, but gases such as nitric oxide, inflammatory factors, oxidative stress systems, apoptotic factors, sympathetic and parasympathetic nervous systems, endocannabinoid systems, and ion channels all play a role. The treatment of cirrhotic cardiomyopathy is primarily limited to animal studies; however, albumin has clinical therapeutic effectiveness.